Search
Search Results
-
Overcoming limitations in current measures of drug response may enable AI-driven precision oncology
Machine learning (ML) models of drug sensitivity prediction are becoming increasingly popular in precision oncology. Here, we identify a fundamental...
-
Predicting drug response from single-cell expression profiles of tumours
BackgroundIntra-tumour heterogeneity (ITH) presents a significant obstacle in formulating effective treatment strategies in clinical practice....
-
Prediction model for drug response of acute myeloid leukemia patients
Despite some encouraging successes, predicting the therapy response of acute myeloid leukemia (AML) patients remains highly challenging due to tumor...
-
Association of drug overdoses and user characteristics of Canada’s national mobile/virtual overdose response hotline: the National Overdose Response Service (NORS)
BackgroundSeveral novel overdose response technology interventions, also known as mobile overdose response services (MORS), have emerged as adjunct...
-
Radiological characteristics predicting early poor drug response in patients with hemifacial spasm
ObjectivesPatients with hemifacial spasm (HFS) often resort to botulinum toxin injections or microvascular decompression surgery when medication...
-
Aberrant functional connectivity associated with drug response in patients with newly diagnosed epilepsy
ObjectiveTo analyze the local functional activity and connectivity features of the brain associated with drug response inpatients newly diagnosed...
-
Intra- and Interpatient Drug Response Heterogeneity Exist in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Nongynecologic Cancers
BackgroundSelect patients with peritoneal metastases are treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy...
-
Predictive value of the systemic immune inflammation index and systemic inflammatory response index on omalizumab drug survival in chronic spontaneous urticaria
BackgroundOmalizumab is recommended as adjunctive therapy for antihistamine-refractory chronic spontaneous urticaria (CSU). However, its long-term...
-
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing
Low-grade serous ovarian cancer (LGSOC) typically responds poorly to standard platinum-based chemotherapy and new therapeutic approaches are needed....
-
Integrative multi-omics and drug–response characterization of patient-derived prostate cancer primary cells
Prostate cancer (PCa) is the second most prevalent malignancy in males across the world. A greater knowledge of the relationship between protein...
-
Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
Background and ObjectivesAs drug development scientists strive to accelerate availability of therapies for patients, model-informed drug development...
-
Mitophagy-related long non-coding RNA signature predicts prognosis and drug response in Ovarian Cancer
BackgroundOvarian cancer (OC) is the most malignant tumor with the worst prognosis in female reproductive system. Mitophagy and long non-coding RNAs...
-
A MiR181/Sirtuin1 regulatory circuit modulates drug response in biliary cancers
Despite recent advances, biliary tract cancer (BTC) remains one of the most lethal tumor worldwide due to late diagnosis, limited therapeutic...
-
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma
BackgroundMultiple myeloma (MM) is an incurable plasma cell malignancy, accounting for approximately 1% of all cancers. Despite recent advances in...
-
Enhancing drug and cell line representations via contrastive learning for improved anti-cancer drug prioritization
Due to cancer’s complex nature and variable response to therapy, precision oncology informed by omics sequence analysis has become the current...
-
Implications of genetic variations, differential gene expression, and allele-specific expression on metformin response in drug-naïve type 2 diabetes
PurposeMetformin is widely used to treat type 2 diabetes mellitus (T2DM) individuals. Clinically, inter-individual variability of metformin response...
-
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes
Acute myeloid leukaemia (AML) patients harbouring certain chromosome abnormalities have particularly adverse prognosis. For these patients, targeted...
-
Relationship between efficacy and common metabolic parameters in first-treatment drug-naïve patients with early non-response schizophrenia: a retrospective study
BackgroundComorbid metabolic disorders in patients with schizophrenia are very common. Patients with schizophrenia who respond to therapy early are...
-
Modelling metabolic diseases and drug response using stem cells and organoids
Metabolic diseases, including obesity, diabetes mellitus and cardiovascular disease, are a major threat to health in the modern world, but efforts to...
-
First reported double drug–drug interaction in a cancer renal patient under everolimus treatment: therapeutic drug monitoring and review of literature
Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) used in both transplantation and cancer treatment (breast, renal and...
